Aripiprazole alone or in combination for acute mania

Abstract

Analysis 1.1. Comparison 1 Aripiprazole versus placebo, Outcome 1 Mean change in YMRS from baseline at three weeks. Analysis 1.2. Comparison 1 Aripiprazole versus placebo, Outcome 2 Mean change in YMRS from baseline at day four. Analysis 1.3. Comparison 1 Aripiprazole versus placebo, Outcome 3 Mean change in YMRS from baseline week four. Analysis 1.4. Comparison 1 Aripiprazole versus placebo, Outcome 4 Mean change in YMRS from baseline at week six. Analysis 1.5. Comparison 1 Aripiprazole versus placebo, Outcome 5 Mean change in YMRS from baseline to week 12.

Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials

“…Comparison to two recent meta-analyses (Brown et al, 2013;Meduri et al, 2016), our study provided more information on the analysis of adverse reactions and preventive efficacy as shown by relapse rates from bipolar mania to bipolar depression. The more recent search dates and stricter inclusion criteria (only RCTs in this meta-analysis) mean that the results of this meta-analysis are more up-to-date compared to the previous reports.…”

“…In addition, the dose-dependent responses and adverse reactions to antipsychotic drugs should be considered with caution; however, aripiprazole has been approved for the treatment of BD in pediatric patients by the FDA in the USA and the EMA in the EU for its efficacy and safety. Furthermore, the previous two studies (Brown et al, 2013;Meduri et al, 2016) also included above two studies into their analyses. However, despite the apparent good tolerability, the results of this meta-analysis should be interpreted with caution for application in clinical practice in pediatric patients.…”

“…Two previous meta-analyses (Brown et al, 2013;Meduri et al, 2016) investigated the efficacy or safety profile of aripiprazole. Brown et al (Brown et al, 2013) discussed the efficacy and adverse reactions in BD; however, the authors only addressed the effects of treatment with regards to episodes of mania without considering the depression or maintenance phase, and their search only included trials before 2013.…”

“…Brown et al (Brown et al, 2013) discussed the efficacy and adverse reactions in BD; however, the authors only addressed the effects of treatment with regards to episodes of mania without considering the depression or maintenance phase, and their search only included trials before 2013. Furthermore, previous analysis of adverse reactions have contained less than three trials, precluding the ability to make definitive conclusions (Davey et al, 2011).…”

“…In addition, the reference lists of review articles relevant to this topic were manually searched to identify potentially eligible papers (Arbaizar et al, 2009;Biederman et al, 2005;Brown et al, 2013;Fountoulakis et al, 2009;Fountoulakis et al, 2011;McKeage, 2014;Meduri et al, 2016;Miura et al, 2014;Perlis, 2007;Perlis et al, 2006;Scherk et al, 2007;Smith et al, 2007;Taylor, 2003;Vieta et al, 2010;Yatham et al, 2013;Yildiz et al, 2015).…”